A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients?

Alessandro Leonetti, Daniela Carbone, Alessandro Gregori, Marcello Tiseo, Godefridus J. Peters, Dongmei Deng, Elisa Giovannetti*

*Corresponding author for this work

Research output: Contribution to JournalComment / Letter to the editorAcademic

Original languageEnglish
Pages (from-to)3135-3137
Number of pages3
JournalJournal of Cancer Research and Clinical Oncology
Issue number10
Early online date26 Apr 2021
Publication statusPublished - Oct 2021

Bibliographical note

Funding Information:
MT has been on advisory boards and received speakers’ fees for Astra-Zeneca, Pfizer, Eli-Lilly, BMS, Novartis, Roche, MSD, Boehringer Ingelheim, Otsuka, Takeda, and Pierre Fabre. MT has received research grants from Astra-Zeneca and Boehringer Ingelheim. AL received speakers’ fees for Astra-Zeneca.

Funding Information:
AL and MT are supported by the AIRC-IG grant# 20,074, AG and EG are supported by the KWF Grant#19,571, GJP and EG are supported by the Polish National Science Center Grant#2018/31/B/NZ7/02,909, DD and EG are supported by Cancer Center Amsterdam Grants 2016 and 2018, EG is supported by the AIRC-IG grant#24,444.

Cite this